Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nobelpharma’s Retympa, Senju’s Aibeta Now Available
December 11, 2019
- Healios Poised to Go into the Black with Sakigake-Designated MultiStem, Revs Up Universal Cell Biz
December 10, 2019
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
- Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
December 10, 2019
- Takeda Updates Failed Ninlaro Trial Results for Amyloidosis
December 10, 2019
- Ono’s BTK Inhibitor Hits ORR of 88.9% in Types of B Cell Lymphomas: Japan PII
December 10, 2019
- Alzheimer’s Disease Might Be Diagnosed by Blood Sample: Sysmex, Eisai
December 10, 2019
- Kissei’s GnRH Receptor Antagonist Shows Efficacy for Uterine Fibroids in Overseas PIII: Interim Analysis
December 10, 2019
- All-Case PMS Requirement Lifted for Xalkori: Pfizer
December 10, 2019
- Fujifilm Toyama Chemical Completes Construction of New Liposome Formulation Manufacturing Facility
December 10, 2019
- MSD, Taiho to Wind Up Keytruda Copromotion at Year-End
December 9, 2019
- All-Case PMS Requirement Lifted for Lenvima’s Thyroid Cancer Use
December 9, 2019
- Japan Ethical Drug Sales Up 1.7% in October: Crecon
December 9, 2019
- Wholesalers’ Bid-Rigging Scandal Might Have Been Exposed via Leniency Program, Further Cases Could Be Laid Bare: Lawyer
December 6, 2019
- Mochida, Idorsia Hook Up on Insomnia Drug in Japan
December 6, 2019
- Fujifilm’s US Bioscience Site Now Up and Running
December 6, 2019
- Daiichi Sankyo Reps Continue Heavy Pitches for Tarlige in September: Impact Track
December 6, 2019
- Keytruda Remains No. 1 in November Japan Drug Ranking: Encise
December 6, 2019
- Boston Biomedical Ties Up with 3 Institutions in Oncology Research
December 5, 2019
- With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar
December 4, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…